Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors

Cancer Research

Volumn 65, Issue 4, 2005, Pages 1523-1531

  Wang, Yaohe ^a   Xue, Shao An ^b   Hallden, Gunnel ^a   Francis, Jennelle ^a   Yuan, Ming ^a   Griffin, Beverly E ^b,c   Lemoine, Nick R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS; VIRUS MESSENGER RNA; VIRUS RNA;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; DELETION MUTANT; GENE DELETION; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER TOXICITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; RNA TRANSLATION; TUMOR; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION; WILD TYPE;

ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; EUKARYOTIC INITIATION FACTOR-2; HERPESVIRUS 4, HUMAN; HUMANS; LIVER; MICE; MICE, INBRED C57BL; NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RNA, VIRAL; VIRUS REPLICATION;

EID: 13944270613     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3113     Document Type: Article

References (57)

1. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol 2000;71:108-17.
2. Rickinson AB, Kieff E. Epstein Barr Virus. In: Knipe DM and Howley PM. Fields Virology, Vol. 2, Philadelphia, PA: Lippincott Williams & Wilkins; 2001. pp. 2597-612.
3. Labrecque L, Barnes D, Fentiman I, Griffin BE. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res 1995;55:39-45.
4. Bonnet M, Guinebretiere J, Kremmer E, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999;91:1376-81.
5. Fina F, Romain S, Ouafik L, et al. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br J Cancer 2001;84:783-90.
6. Wong M, Chung L, Yuen S, et al. In situ detection of Epstein-Barr virus in non-small cell lung carcinomas. J Pathol 1995;177:233-40.
7. Grinstein S, Preciado M, Gattuso P, et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 2002;62:4876-8.
8. Morbini P, Riboni R, Tomaselli S, Rossi A, Magrini U. EBER- and LMP-1-expressing pulmonary lymphoepithelioma-like carcinoma in a Caucasian patient Hum Pathol 2003;34:623-5.
9. Huber M, Pavlova B, Muhlberger H, Hollaus P, Lintner F. Detection of the Epstein-Barr virus in primary adenocarcinoma of the lung with Signet-ring cells. Virchows Arch 2002;44:25-30.
10. Sugawara Y, Makuuchi M, Takada K. Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand J Gastroenterol 2000;35:981-4.
11. Chen P, Pan C, Hsu W, Ka H, Yang A. Epstein-Barr virus-associated lymphoepithelioma-like carcinoma of the esophagus. Hum Pathol 2003;34:407-11.
12. Hawkins L, Lemoine N, Kim D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol 2002;3: 17-26.
13. Kirn D. Clinical research results with dl1520 (Onyx015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001;8:89-98.
14. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000;19:6660-9.
15. Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003;21:1328-35.
16. Earl P, Jones E, Moss B. Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene. Proc Natl Acad Sci U S A 1986;83:3659-63.
17. Parker G, Crook T, Bain M, Sara E, Farrell P, Allday M. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 1996;13:2541-9.
18. Horvath J, Faxing C, Weber J. Complementation of adenovirus early region 1a and 2a mutants by Epstein-Barr virus immortalized lymphoblastoid cell lines. Virology 1991;184:141-8.
19. Sharp T, Schwemmle M, Jeffrey I, et al. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res 1993;21:4483-90.
20. Sharp TV, Raine DA, Gewert DR, Joshi B, Jagus R, Clemens M. Activation of the interferon-inducible (2′-5′) oligoadenylate synthetase by the Epstein-Barr virus RNA, EBER-1. Virology 1999;257:303-13.
21. Rechel PA, Merrick WC, Siekierka J, Mathews M. Regulation of a protein synthesis initiation factor by adenovirus virus-associated RNA1. Nature 1985;313:196-200.
22. Soderlund H, Pettersson U, Vennstrom B, Philipson L, Mathews M. A new species of virus coded low molecular weight RNA from cells infected with adenovirus type2. Cell 1976;7;585-93.
23. Mathews M. Genes for VA-RNA in adenovirus 2. Cell 1975;6:223-9.
24. Schneider RJ, Weinberger C, Shenk T. Adenovirus VAI RNA facilitates the initiation of translation in virus-infected cells. Cell 1984;37:291-8.
25. Thimmappaya B, Weinberger C, Schneider RJ, Shenk T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 1982;31:543-51.
26. Katze M, Decarato D, Sfer B, Galabru J, Hovanessian G. Adenovirus VAI RNA complexes with 68,000 Mr protein kinase to regulate its phosphorylation and activity. EMBO J 1987;6:689-98.
27. Kitajewski JR, Schneider RJ, Safer B, et al. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2α kinase. Cell 1986;45:195-200.
28. Schneider RJ, Safer B, Munemitsu SM, Samuel CE, Shenk T. Adenovirus VAI RNA prevents phosphorylation of the eukaryotic initiation factor 2α subunit subsequent to infection. Proc Natl Acad Sci U S A 1985;82:4321-4.
29. Siekierka J, Mariano T, Reichel PA, Mathews M. Translational control by adenovirus: lack of virus associated RNAI during adenovirus infection results in phosphorylation of initiation factor eIF-2 and inhibition of protein synthesis. Proc Natl Acad Sci U S A 1985;82:1959-63.
30. Rosa M, Gottlieb E, Lerner MR, Steitz J. Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAII. Mol Cell Biol 1981;1:785-96.
31. Desai SY, Patel RC, Sen GC, Malhotra P, Ghadge GD, Thimmapaya B. Activation of interferon-inducible 2′-5′ oligoadenylate synthetase by adenoviral VAI RNA. J Biol Chem 1995;270:3454-61.
32. Bhat RA, Thimmappaya B. Two small RNAs encoded by Epstein-Barr virus can functionally substitute for the virus-associated RNAs in the lytic growth of adenovirus 5. Proc Natl Acad Sci U S A 1983;80:4789-93.
33. Bhat RA, Thimmappaya B. Construction and analysis of additional adenovirus substitution mutants confirm the complementation of VAI RNA function by two small RNAs encoded by Epstein-Barr virus. J Virol 1985;56:750-6.
34. Cheung S, Huang D, Hui A, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999;83:121-6.
35. Pilder S, Logan J, Shenk T. Deletion of the gene encoding the adenovirus 5 early region 1b 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA. J Virol 1984;52:664-71.
36. Hallden G, Hill R, Wang Y, et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003;8:412-24.
37. Kitajewski J, Schneider RJ, Safer B, Shenk T. An adenovirus mutant unable to express VAI RNA displays different growth responses and sensitivity to interferon in various host cell lines. Mol Cell Biol 1986;6:4493-8.
38. Rajan P, Swaminathan S, Zhu J, et al. A novel translational regulation function for the simian virus 40 large-T antigen gene. J Virol 1995;69:785-95.
39. Jakubczak JL, Ryan P, Gorziglia M, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003;63:1490-9.
40. Xue S, Lu Q, Poulsom R, Karran L, Jones M, Griffin BE. Expression of two related viral early genes in Epstein-Barr virus-associated tumors. J Virol 2000;74:2793-803.
41. Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003;63:5544-50.
42. Meurs E, Chong K, Glabru J, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990;62:379-90.
43. Clark P, Schwemmle M, Schickinger J, Hilse K, Clemens MJ. Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic Acids Res 1991;19:243-8.
44. Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002;9:1062-7.
45. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002;1:325-37.
46. Israel B, Kenney S. Virally targeted therapies for EBV-associated malignancies. Oncogene 2003;22:5122-30.
47. Clemens MJ. Protein kinase that phosphorylated eIF-2 and eIF2B, and their role in eukaryotic cell translational control. In: Hershe J, Mathews M, Sonenber N, editors. Translational control. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1996. p. 139-72.
48. Laing K, Elia A, Jefre I, et al. In vivo effects of the Epstein-Barr virus small RNA EBER-1 on protein synthesis and cell growth regulation. Virology 2002;297:253-69.
49. Lei M, Liu Y, Samuel C. Adenovirus VAI RNA antagonizes the RNA-editing activity of the ADAP adenosine deaminase. Virology 1998;245:188-96.
50. Vorburger SA, Pataer A, Yoshida K, et al. Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis. Oncogene 2002;21:6278-88.
51. Jeffrey IW, Bushell M, Tilleray V, Morley S, Clemens M. Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor-α family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase. Cancer Res 2002;62:2272-80.
52. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla KN, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 1998;17:6888-902.
53. Donze O, Dostie J, Sonenberg N. Regulatable expression of the interferon-induced double-stranded RNA dependent protein kinase PKR induces apoptosis and Fas receptor expression. Virology 1999;256:322-9.
54. Xiang Y, Condit R, Vijaysri S, Jacobs B, Williams B, Silverman R. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol 2002;76:5251-9.
55. Liu T, Hallden G, Wang Y, et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004;9:786-803.
56. Medina D, Sheay W, Goodell L, et al. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells. Blood 1999;94:3499-508.
57. Wang Y, Tan P, Francis J, et al. Anti-CD22 immunolipoplexes enhance transduction of adenovirus in B lymphoma cells independent of adenovirus receptor but do not enhance the cytotoxicity of oncolytic adenovirus. Mol Ther 2004;9:S171.